Table 1.

Schedule of enrolment, interventions and assessment in the DisCoVeRy trial

Day±window	Screening	Baseline*	D1	D2-D14†	D15† ±2	D29† ±3	D90
Eligibility
Informed consent	X
Demographics and medical history	X
EKG	X
Review SARS-CoV-2 PCR results	X
Study intervention
Randomisation		X
Standard of Care (SoC)
Or SoC plus administration of lopinavir/ritonavir			Lopinavir/ritonavir for 14 days
Or SoC plus administration of lopinavir/ritonavir in association with interferon ß1a			Lopinavir/ritonavir for 14 days Interferon ß−1a day 1, day 3, day 6 or until discharge (after at least two doses)
Or SoC plus administration of remdesivir			Daily administration until discharge (after at least 5 days) or day 10
Or SoC plus administration of hydroxychloroquine			Daily administration until day 10
Study procedures
Vital signs including SpO2		X	X	Daily until discharge	X	X
Clinical data collection		X	X	Daily until discharge	X	X	X
Electrocardiogram (EKG)‡	X			Days 3, 5 and 8
Medication review	X		X	Daily until discharge	X	X
Adverse event evaluation			X	Daily until discharge	X	X	X
Safety laboratory
Safety haematology, chemistry and liver tests	X§	X¶		Days 3, 5, 8 and 11 (all ±1 day)	X	X
Pregnancy test for females of childbearing potential	X§				X	X
Plasma concentration of lopinavir			X	Days 3, 6, 8 and 11 (all ±1 day)
Plasma concentration of hydroxychloroquine			X	Days 3, 5, 8 and 11 (all ±1 day)
Plasma and intracellular concentration of remdesivir			X	Days 2, 5 and 8 if hospitalised
Plasma concentration of interferon ß−1a				Days 3 to 6 if hospitalised
Research laboratory
Biobank (whole blood and plasma)**		X**		Days 3, 5, 8 and 11 (all ±1 day)	X	X
Plasma for PCR SARS-CoV-2††		X		Day 3, 5, 8 and 11 (all ±1 day)
Nasopharyngeal swab or lower respiratory tract samples††		X		Day 3, 5, 8 and 11 (all ±1 day)	X	X
Thoracic CT scan or chest X-ray		X		Day 8 (±1 day)	X	X
Whole blood for genetic analysis		X

*Baseline assessments should be performed prior to study drug administration.

†If discharged from the hospital, visits and safety assessments are conducted in the outpatient setting.

‡An electrocardiogram (EKG) with calculation of the corrected QT (Fridericia formula) is reviewed at screening and monitored at Day 3, 5 and 8 in patients treated with hydroxychloroquine.

§Laboratory tests performed in the 48 hours prior to enrolment are accepted for determination of eligibility.

¶Any laboratory tests performed in the 24 hours before randomisation can be used for baseline and Day 1.

**For the biobank, whole blood is only collected at baseline.

††For each sample, the viral load is measured by a specific SARS-COV-2 real-time (RT)-PCR and normalised according the number of cells in each sample. This method is validated to monitor viral load kinetics over time and expressed in standardised unit log of number of viral copies/10 000 cells.

D, day.